Literature DB >> 1713363

Preliminary experience with FK506 in thoracic transplantation.

J M Armitage1, R L Kormos, J Fung, J Lavee, F J Fricker, B P Griffith, R S Stuart, G C Marrone, R L Hardesty, S Todo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1713363      PMCID： PMC3032445          DOI： 10.1097/00007890-199107000-00038

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  5 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Early trials with FK 506 as primary treatment in liver transplantation.

Authors:  S Todo; J J Fung; A J Demetris; A Jain; R Venkataramanan; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

4.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

5.  Optimal perioperative immunosuppression in cardiac transplantation using rabbit antithymocyte globulin.

Authors:  R L Kormos; J M Armitage; J S Dummer; Y Miyamoto; B P Griffith; R L Hardesty
Journal:  Transplantation       Date:  1990-02       Impact factor: 4.939
  5 in total
  6 in total

Review 1.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

2.  The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver.

Authors:  K Abu-Elmagd; J J Fung; M Alessiani; A Jain; R Venkataramanan; V S Warty; S Takaya; S Todo; W D Shannon; T E Starzl
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939

3.  Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.

Authors:  K Tamura; J Woo; N Murase; G Carrieri; M A Nalesnik; A W Thomson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 4.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

5.  Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.

Authors:  A W Thomson; J Woo; G Z Yao; S Todo; T E Starzl; A Zeevi
Journal:  Transpl Immunol       Date:  1993       Impact factor: 1.708

6.  Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen.

Authors:  Matthias Helmschrott; Jan Beckendorf; Ceylan Akyol; Arjang Ruhparwar; Bastian Schmack; Christian Erbel; Christian A Gleissner; Mohammadreza Akhavanpoor; Philipp Ehlermann; Tom Bruckner; Hugo A Katus; Andreas O Doesch
Journal:  Drug Des Devel Ther       Date:  2014-09-09       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.